Bonus Biogroup will begin a clinical trial of the drug for Corona – the capital market

Company

Bonus Biogroup
+ 17.8%

Base:59

opening:60

Tall:74.5

low:60

change:10,807,220

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Reports that it has received approval to begin clinical trials with a drug developed by MesenCure for the treatment of corona patients. The trial will be performed on about 60 patients of a wide age range at Rambam Hospital in Haifa. Many reduce the storm but they have not succeeded, “explains Bonus Biogroup CEO Dr. Shai Maretzky in a conversation with BizPortal,” Our drug is cellular and developed in advance to reduce the overactivity of the immune system. ”

The outline for the clinical trial is based, among other things, on the preclinical trial in which the treatment succeeded in rescuing from the death of animals suffering from fatal pneumonia, after the second dose out of three doses of the drug. Mazencure will be given by injection to corona patients and in the meantime against the background of the increase in morbidity, in Israel and in other countries, Bonus Biogroup claims that its use may help avoid locksmiths, whose role is to prevent the collapse of the medical system.

“The drug will be given by injection to patients who are at the peak of a cytokine storm or are just entering it,” Maretzky says, “and it will help stabilize them so that they do not reach a state of anesthesia and respiration.”

How long is the experiment expected to take?
“I can say that these are not long trials because the results of the treatment are seen in a short period of time. So if when we grow a bone, our main field of activity, the polo-up is a year, then here it is much shorter, also because there are many patients from whom the results will be obtained. “.

You say that even when the corona is expected to pass the drug will still be useful, and that it is turning to a market that will roll in $ 40 billion a year for another five years. What other situations does it address?
“For other reactions in respiratory problems caused by an overreaction of the immune system – it can be respiratory infections, asthma and various lung diseases. There are many patients in the world.”

But these are familiar symptoms, why do you need your treatment?
“There are a lot of reasons for respiratory infections, it could be bacterial based and then we are less relevant and will use antibiotic treatment. But in viral cases involving a cytokine storm, which is very common, it will put us at the forefront. As for cell therapy, there were groups around the world trying to take cells “Developed for a specific indication, such as lower limb sclerosis, muscle or heart treatment, and tried to inject it into corona patients thinking it might help them. But the chances of getting the desired result are low. We first developed such cells specifically for this purpose.”

Bonus develops tissue engineering technology for growing live human bone grafts. The company is in the second phase of two clinical trials, one with skull-free implants and the other with no limbs. At the end of last December, it was reported that the drug for Sjogren’s syndrome, developed by Wize Pharma, from which it will receive a 37% bonus of revenue, showed an improvement in dry eye symptoms in patients as part of the clinical trial.

In the third quarter of 2020, the company reduced its losses to NIS 3.3 million, compared with NIS 4.7 million in the corresponding period. During the reporting period, starting in June, and with the progress in the development of the treatment in Corona, the company returned all employees who were expelled and returned to full employment. The total loss in the first 9 months of 2020 was estimated at NIS 14.5 million, compared to NIS 17.5 million in the corresponding period. To BizPortal from last October, Dr. Shai Maretzky, the company’s CEO, and Dr. Tomer Bornstein, its research director, explained the results at the time by saying that the clinical trials took a long time.

Since the beginning of the month, a bonus share has risen by about 20%, among other things after completing an 11% premium increase on the market price. The company raised NIS 13 million at a price of 51.7 agorot per share, while the closing price the day before was 46.4. The SIBF venture capital fund from Be’er Sheva took part in the offering, along with another investor. SIBF also participated in the previous raising of the Biogroup bonus in October, when it invested NIS 7 million in the company. The bonus is currently traded at a price of 72 agorot per share, which reflects a value of NIS 600 million. “The money will be used to continue the developments and clinical trials, to enter further indications,” says Maretzky, adding, “We also have new products in research and development and when things mature we will have something to tell.”